ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma

This study is ongoing, but not recruiting participants.

Sponsored by: European Organization for Research and Treatment of Cancer
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00041236
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have advanced soft tissue sarcoma.


Condition Intervention Phase
Sarcoma
Drug: exatecan mesylate
Phase II

MedlinePlus related topics:   Cancer    Soft Tissue Sarcoma   

ChemIDplus related topics:   Exatecan mesylate    Exatecan   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Open Label
Official Title:   Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group

Further study details as provided by National Cancer Institute (NCI):

Study Start Date:   May 2002

Detailed Description:

OBJECTIVES:

  • Determine the anticancer activity of exatecan mesylate, in terms of objective response and duration of response, in patients with advanced soft tissue sarcoma.
  • Determine the safety of this drug in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to histological diagnosis (leiomyosarcoma vs other histologies).

Patients receive exatecan mesylate IV over 30 minutes daily on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 6 weeks until disease progression. After disease progression, patients are followed every 12 weeks for survival.

PROJECTED ACCRUAL: A total of 32-50 patients (16-25 per stratum) will be accrued for this study.

  Eligibility
Ages Eligible for Study:   15 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed soft tissue sarcoma

    • Malignant fibrous histiocytoma
    • Liposarcoma
    • Rhabdomyosarcoma
    • Synovial sarcoma
    • Malignant paraganglioma
    • Fibrosarcoma
    • Leiomyosarcoma
    • Angiosarcoma including hemangiopericytoma
    • Malignant peripheral nerve sheath tumor
    • Unclassified sarcoma
    • Miscellaneous sarcoma including mixed mesodermal tumors of the uterus
  • The following tumor types are excluded:

    • Gastrointestinal stromal tumor
    • Chondrosarcoma
    • Malignant mesothelioma
    • Neuroblastoma
    • Osteosarcoma
    • Ewing's sarcoma
    • Embryonal rhabdomyosarcoma
  • Prior chemotherapy for metastatic disease required

    • One line of combination chemotherapy containing anthracycline OR
    • No more than 2 single-agent regimens including anthracycline
    • Adjuvant chemotherapy not considered first line unless tumor progresses within 6 months after treatment
  • Must have 1 measurable lesion

    • Clinical evidence of progression within 6 weeks prior to study
    • Osseous lesions and pleural effusions not considered measurable
  • No known or symptomatic CNS metastases

PATIENT CHARACTERISTICS:

Age:

  • 15 to 75

Performance status:

  • WHO 0-1

Life expectancy:

  • Not specified

Hematopoietic:

  • WBC at least 4,000/mm^3
  • Platelet count at least 100,000/mm^3

Hepatic:

  • Bilirubin no greater than 1.8 mg/dL
  • Albumin at least 2.5 g/dL

Renal:

  • Creatinine no greater than 1.4 mg/dL OR
  • Creatinine clearance greater than 65 mL/min

Cardiovascular:

  • No history of severe cardiovascular disease

Other:

  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for up to 6 months after study participation
  • No other severe medical illness, including psychosis
  • No other prior or concurrent malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • See Disease Characteristics
  • More than 4 weeks since prior chemotherapy
  • No other concurrent cytotoxic therapy

Endocrine therapy:

  • Not specified

Radiotherapy:

  • No radiotherapy to the sole measurable lesion
  • No concurrent radiotherapy

Surgery:

  • Not specified

Other:

  • No other investigational drugs for 28 days prior to, during, and for 28 days after completion of study drug
  • No other concurrent anticancer therapy
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00041236

Locations
Belgium
Cliniques Universitaires Saint-Luc    
      Brussels, Belgium, 1200
U.Z. Gasthuisberg    
      Leuven, Belgium, B-3000
Denmark
Aarhus University Hospital - Aarhus Sygehus - Norrebrogade    
      Aarhus, Denmark, DK-8000
Germany
Eberhard Karls Universitaet    
      Tuebingen, Germany, D-72076
Medizinische Hochschule Hannover    
      Hannover, Germany, D-30625
Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch    
      Berlin, Germany, D-13122
Universitaetsklinikum Essen    
      Essen, Germany, D-45122
Universitaets-Krankenhaus Eppendorf    
      Hamburg, Germany, D-20246
Universitatsklinikum Carl Gustav Carl Carus    
      Dresden, Germany, D-01307
Slovakia
National Cancer Institute - Bratislava    
      Bratislava, Slovakia, 833 10

Sponsors and Collaborators
European Organization for Research and Treatment of Cancer

Investigators
Investigator:     Peter Reichardt, MD     Robert Roessle Comprehensive Cancer Center - Charite Campus Buch    
  More Information


Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site
 

Publications of Results:
Reichardt P, Nielsen OS, Bauer S, Hartmann JT, Schoffski P, Christensen TB, Pink D, Daugaard S, Marreaud S, Van Glabbeke M, Blay JY. Exatecan in pretreated adult patients with advanced soft tissue sarcoma: Results of a phase II - Study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2007 Feb 28; [Epub ahead of print]
 
Pink D, Reichardt P, Nielsen OS, et al.: Exatecan (DX-8951f), a new topoisomerase I - inhibitor, is inactive in heavily pretreated patients (pts.) with advanced soft tissue sarcoma (STS): a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. [Abstract] J Clin Oncol 23 (Suppl 16): A-9058, 830s, 2005.
 

Study ID Numbers:   CDR0000069455, EORTC-62006
First Received:   July 8, 2002
Last Updated:   July 23, 2008
ClinicalTrials.gov Identifier:   NCT00041236
Health Authority:   United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
adult angiosarcoma  
adult fibrosarcoma  
adult leiomyosarcoma  
adult liposarcoma  
adult neurofibrosarcoma  
adult synovial sarcoma  
stage IV adult soft tissue sarcoma  
recurrent adult soft tissue sarcoma
adult malignant fibrous histiocytoma
adult malignant hemangiopericytoma
adult rhabdomyosarcoma
stage IV uterine sarcoma
recurrent uterine sarcoma
uterine leiomyosarcoma

Study placed in the following topic categories:
Histiocytoma, Malignant Fibrous
Fibrosarcoma
Leiomyosarcoma
Histiocytoma, Benign Fibrous
Synovial sarcoma
Malignant mesenchymal tumor
Osteosarcoma
DX 8951
Hemangiosarcoma
Osteogenic sarcoma
Hemangiopericytoma
Camptothecin
Soft tissue sarcomas
Recurrence
Sarcoma, Synovial
Neoplasms, Connective and Soft Tissue
Liposarcoma
Histiocytoma
Sarcoma
Uterine sarcoma
Malignant fibrous histiocytoma
Rhabdomyosarcoma

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Therapeutic Uses
Enzyme Inhibitors
Antineoplastic Agents, Phytogenic
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers